Truist Financial
XBI icon

Truist Financial’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Truist Financial’s Portfolio XBI Stock Details XBI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.81M Sell
17,756
-15
-0.1% -$2.03K ﹤0.01% 1197
2026
Q1 		$2.27M Buy
17,771
+6,046
+52% +$755K ﹤0.01% 1240
2025
Q4 		$1.43M Sell
11,725
-2,746
-19% -$315K ﹤0.01% 1491
2025
Q3 		$1.45M Sell
14,471
-1,390
-9% -$125K ﹤0.01% 1505
2025
Q2 		$1.32M Sell
15,861
-5,213
-25% -$416K ﹤0.01% 1469
2025
Q1 		$1.71M Sell
21,074
-22,826
-52% -$2.04M ﹤0.01% 1296
2024
Q4 		$3.95M Buy
43,900
+9,746
+29% +$944K 0.01% 933
2024
Q3 		$3.37M Buy
34,154
+1,381
+4% +$136K 0.01% 998
2024
Q2 		$3.04M Buy
32,773
+252
+0.8% +$22.6K ﹤0.01% 1081
2024
Q1 		$3.09M Sell
32,521
-88
-0.3% -$8.17K ﹤0.01% 1084
2023
Q4 		$2.91M Sell
32,609
-6,625
-17% -$492K ﹤0.01% 1079
2023
Q3 		$2.86M Sell
39,234
-185
-0.5% -$14.8K ﹤0.01% 1063
2023
Q2 		$3.28M Sell
39,419
-9,837
-20% -$823K 0.01% 1020
2023
Q1 		$3.75M Buy
49,256
+7,017
+17% +$582K 0.01% 948
2022
Q4 		$3.51M Buy
42,239
+3,499
+9% +$283K 0.01% 954
2022
Q3 		$3.07M Sell
38,740
-28,620
-42% -$2.41M 0.01% 972
2022
Q2 		$5M Sell
67,360
-11,692
-15% -$878K 0.01% 804
2022
Q1 		$7.11M Buy
79,052
+40,703
+106% +$3.76M 0.01% 758
2021
Q4 		$4.29M Sell
38,349
-5,731
-13% -$691K 0.01% 941
2021
Q3 		$5.54M Sell
44,080
-168
-0.4% -$21.6K 0.01% 840
2021
Q2 		$5.99M Sell
44,248
-2,430
-5% -$319K 0.01% 812
2021
Q1 		$6.33M Buy
46,678
+139
+0.3% +$20.8K 0.01% 759
2020
Q4 		$6.55M Buy
46,539
+864
+2% +$111K 0.01% 733
2020
Q3 		$5.09M Buy
45,675
+7,567
+20% +$848K 0.01% 740
2020
Q2 		$4.27M Buy
38,108
+8,108
+27% +$799K 0.01% 760
2020
Q1 		$2.32M Buy
30,000
+11,377
+61% +$1.01M 0.01% 923
2019
Q4 		$1.77M Buy
+18,623
New +$1.61M ﹤0.01% 1187

Other funds holding XBI

Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
MIH
Meitav Investment House Bene-Beraq, Israel $14.9B AUM 46.8% 1-Year Est. Return
MSR
Main Street Research Lakeville, Connecticut $2.12B AUM 67.44% 1-Year Est. Return
PR
PSP Research Newtown Square, Pennsylvania $188M AUM
AssetMark Inc
AssetMark Inc Concord, California $58.2B AUM 22.78% 1-Year Est. Return
SO
STRS Ohio Columbus, Ohio $26.7B AUM 43.32% 1-Year Est. Return
WT
Whittier Trust South Pasadena, California $10.2B AUM 33.39% 1-Year Est. Return
AAS
Annex Advisory Services Brookfield, Wisconsin $5.86B AUM 21.83% 1-Year Est. Return
WJWM
Williams Jones Wealth Management New York $8.86B AUM 22.16% 1-Year Est. Return
G
GenTrust Miami, Florida $2.6B AUM 18.42% 1-Year Est. Return

Truist Financial's XBI Position: Q2 2026 in Review

Truist Financial reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 0.08% in Q2 2026, selling an estimated $2.03K and leaving 17,756 shares worth $2.81M. The position accounts for ﹤0.01% of the portfolio, ranked #1197.

Truist Financial first reported a position in XBI in Q4 2019 and has held it in 27 quarters since. The position peaked at $7.11M in Q1 2022. 519 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

  • Truist Financial held 17,756 shares of State Street SPDR S&P Biotech ETF worth $2.81M as of Q2 2026.
  • Truist Financial sold 15 State Street SPDR S&P Biotech ETF shares in Q2 2026, an estimated $2.03K.
  • State Street SPDR S&P Biotech ETF made up ﹤0.01% of Truist Financial's portfolio in Q2 2026, its #1197 holding.
  • Truist Financial first reported a position in State Street SPDR S&P Biotech ETF in Q4 2019 and has held it in 27 quarters since.
  • Truist Financial's State Street SPDR S&P Biotech ETF position peaked at $7.11M in Q1 2022.
  • 519 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on Truist Financial's 13F filing for Q2 2026, filed 28 Jul 2026.